Effects of LAMA/LABA Alone and in Combination on Cardiac Safety

Stefan Andreas 1, 2 1Department of Cardiology and Pneumology, University Medical Centre Göttingen, Göttingen, Germany; 2LungClinic Immenhausen, Immenhausen, Germany, Member of the German Center for Lung Research (DZL) Correspondence: Stefan AndreasDepartment of Cardiology and Pne...

Full description

Bibliographic Details
Main Author: Andreas S
Format: Article
Language:English
Published: Dove Medical Press 2020-08-01
Series:International Journal of COPD
Subjects:
n/a
Online Access:https://www.dovepress.com/effects-of-lamalaba-alone-and-in-combination-on-cardiac-safety-peer-reviewed-article-COPD
id doaj-75bf9104daf447b7b775f428a79e004f
record_format Article
spelling doaj-75bf9104daf447b7b775f428a79e004f2020-11-25T03:07:23ZengDove Medical PressInternational Journal of COPD1178-20052020-08-01Volume 151931193356091Effects of LAMA/LABA Alone and in Combination on Cardiac SafetyAndreas SStefan Andreas 1, 2 1Department of Cardiology and Pneumology, University Medical Centre Göttingen, Göttingen, Germany; 2LungClinic Immenhausen, Immenhausen, Germany, Member of the German Center for Lung Research (DZL) Correspondence: Stefan AndreasDepartment of Cardiology and Pneumology, Herzzentrum Gottingen, Robert-Koch-Str. 40, Göttingen, GermanyTel +49 05673 501 1112Fax +49 05673-501-1101Email stefan.andreas@med.uni-goettingen.deChronic obstructive pulmonary disease (COPD) is a multidimensional, progressive condition characterized by airflow obstruction, worsening dyspnea and respiratory failure.1 The Global Initiative for Chronic Obstructive Lung Disease (GOLD) report suggests that long-acting β 2-agonists (LABAs) or long-acting muscarinic antagonists (LAMAs) are the preferred initial pharmacologic therapy option in the majority of patients with COPD, with escalation to dual therapy as required. 1Extensive clinical data show that the LAMA tiotropium (SPIRIVA®; Boehringer Ingelheim Pharma GmbH, Ingelheim, Germany) delivered as a dry powder formulation by HandiHaler® (DPI; 18 μg nominal dose) or as an aqueous solution via the Respimat® Soft Mist™ inhaler (SMI; 5 μg nominal dose) can improve lung function, symptoms and outcomes, such as dyspnea and quality of life, and reduce exacerbations in patients with COPD. 2 Olodaterol (Striverdi®; Boehringer Ingelheim Pharma GmbH & Co K.G., Ingelheim, Germany) is a LABA that provides 24-hr bronchodilation, and has been shown to improve lung function and reduce symptoms in patients with COPD. 3 When given in a fixed-dose combination with tiotropium via the SMI (Spiolto®; Boehringer Ingelheim Pharma GmbH & Co K.G., Ingelheim, Germany), further improvements in lung function and health-related quality of life have been reported. 4  https://www.dovepress.com/effects-of-lamalaba-alone-and-in-combination-on-cardiac-safety-peer-reviewed-article-COPDn/a
collection DOAJ
language English
format Article
sources DOAJ
author Andreas S
spellingShingle Andreas S
Effects of LAMA/LABA Alone and in Combination on Cardiac Safety
International Journal of COPD
n/a
author_facet Andreas S
author_sort Andreas S
title Effects of LAMA/LABA Alone and in Combination on Cardiac Safety
title_short Effects of LAMA/LABA Alone and in Combination on Cardiac Safety
title_full Effects of LAMA/LABA Alone and in Combination on Cardiac Safety
title_fullStr Effects of LAMA/LABA Alone and in Combination on Cardiac Safety
title_full_unstemmed Effects of LAMA/LABA Alone and in Combination on Cardiac Safety
title_sort effects of lama/laba alone and in combination on cardiac safety
publisher Dove Medical Press
series International Journal of COPD
issn 1178-2005
publishDate 2020-08-01
description Stefan Andreas 1, 2 1Department of Cardiology and Pneumology, University Medical Centre Göttingen, Göttingen, Germany; 2LungClinic Immenhausen, Immenhausen, Germany, Member of the German Center for Lung Research (DZL) Correspondence: Stefan AndreasDepartment of Cardiology and Pneumology, Herzzentrum Gottingen, Robert-Koch-Str. 40, Göttingen, GermanyTel +49 05673 501 1112Fax +49 05673-501-1101Email stefan.andreas@med.uni-goettingen.deChronic obstructive pulmonary disease (COPD) is a multidimensional, progressive condition characterized by airflow obstruction, worsening dyspnea and respiratory failure.1 The Global Initiative for Chronic Obstructive Lung Disease (GOLD) report suggests that long-acting β 2-agonists (LABAs) or long-acting muscarinic antagonists (LAMAs) are the preferred initial pharmacologic therapy option in the majority of patients with COPD, with escalation to dual therapy as required. 1Extensive clinical data show that the LAMA tiotropium (SPIRIVA®; Boehringer Ingelheim Pharma GmbH, Ingelheim, Germany) delivered as a dry powder formulation by HandiHaler® (DPI; 18 μg nominal dose) or as an aqueous solution via the Respimat® Soft Mist™ inhaler (SMI; 5 μg nominal dose) can improve lung function, symptoms and outcomes, such as dyspnea and quality of life, and reduce exacerbations in patients with COPD. 2 Olodaterol (Striverdi®; Boehringer Ingelheim Pharma GmbH & Co K.G., Ingelheim, Germany) is a LABA that provides 24-hr bronchodilation, and has been shown to improve lung function and reduce symptoms in patients with COPD. 3 When given in a fixed-dose combination with tiotropium via the SMI (Spiolto®; Boehringer Ingelheim Pharma GmbH & Co K.G., Ingelheim, Germany), further improvements in lung function and health-related quality of life have been reported. 4  
topic n/a
url https://www.dovepress.com/effects-of-lamalaba-alone-and-in-combination-on-cardiac-safety-peer-reviewed-article-COPD
work_keys_str_mv AT andreass effectsoflamalabaaloneandincombinationoncardiacsafety
_version_ 1724670758607650816